GLP2 10mg

This dual GLP-1/GIP receptor agonist reduces HbA1c levels by 1.87-2.07% in type 2 diabetes patients, significantly outperforming single-hormone medications like semaglutide.

Clinical trials show 20-40% reductions in triglycerides and modest decreases in systolic blood pressure (2-7 mmHg), contributing to cardiovascular risk reduction.

The medication improves insulin sensitivity by up to 30% while reducing fasting insulin levels, helping reverse the underlying metabolic dysfunction rather than just managing symptoms.

Beyond diabetic complications, enhanced glucose control may protect against vascular dementia and Alzheimer's disease, as chronic hyperglycemia damages brain blood vessels.

Most patients experience peak blood sugar improvements within 12-20 weeks of starting treatment, with continued metabolic benefits as long as therapy continues.